PLACEHOLDER: Free shipping over $XX — confirm threshold

Topical cosmetics and devices only — not for injection

Cellular Sequence

Peptide Encyclopaedia

For research purposes onlyResearch onlyNot approved for human use

ACE-031

Also known as Ramatercept-related ActRIIB decoy.

Research / investigational listing only. This compound is not available for consumer purchase from Cellular Sequence and must not be confused with shop products.

Research / investigational compoundThis compound does not have an established approved therapeutic dosing schedule. Doses below describe those reported in published scientific research and should not be interpreted as a treatment recommendation.

At-a-glance profile

Classification
Activin-receptor decoy (research / halted development)
Approval status
Research only · Not approved for human use
Research status
Investigational / reference listing.
Molecular formula
Insufficient reliable evidence identified.
Molecular weight
Insufficient reliable evidence identified.
Sequence
Soluble ActRIIB fusion protein — not a short cosmetic peptide.
Primary biological target
Insufficient reliable evidence identified.
Half-life
Insufficient reliable evidence identified.
Routes investigated
Insufficient reliable evidence identified.
Human evidence level
D — Primarily animal / preclinical evidence

What is it?

Myostatin-pathway research biologic whose development was discontinued amid safety concerns. Not sold.

Mechanism of action

Ligand trap for myostatin/activin family.

Would affect muscle and other TGF-β ligands if bioactive — high risk class.

What is it being studied for?

  • Experimental muscular dystrophy programmes (halted)

Investigational findings are not proven clinical benefits unless an authority has labelled that indication.

Evidence level

Overall human evidence grade: D · Primarily animal / preclinical evidence

Human research

Development stopped; not a consumer product.

Preclinical research

Animal, cell and in-vitro findings are listed separately from human effects.

Myostatin biology.

Doses reported in published research

This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.

Doses reported in human studies

Insufficient reliable evidence identified.

Preclinical / animal study dosing

Insufficient reliable evidence identified.

Pharmacokinetics

Reliable human pharmacokinetic data were not identified for this encyclopaedia entry, or are limited to product information for approved presentations.

Safety

Bleeding and other signals reported in development.

Unknowns. Absence of a published harm signal is not evidence of safety.

Contraindications. Not for human use.

Regulatory status

Not approved.

Educational warning.

Citations

  1. [1] Encyclopaedia note

    Encyclopaedia note

For educational and research reference only. This page summarises published scientific literature and does not constitute medical advice, prescribing information or a recommendation to use an investigational compound. Research doses shown describe doses reported in published studies and are not personalised dosing instructions.

Last reviewed 2026-09-13. Research areas: Performance · Compare peptides